November 18, 2026

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director and Co-CEO
Colin Novick
Representative: Representative Director and Co-CEO
Jason Sieger
(Securities Code: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director and CFO Yasushi Hosono
(https://innovacell.com/contact/?lang=en)

Notice Regarding the Publication of an Interview with Our Co-CEOs in JETRO's "Expert Perspectives" Section of "Investing in Japan"

We are pleased to announce that an interview with our Co-CEOs, Colin Novick and Jason Sieger, has been published in the "Expert Perspectives" series on "Investing in Japan," a website operated by the Japan External Trade Organization (JETRO) to promote investment in Japan.

In the article, our Co-CEOs discuss Innovacell's regenerative medicine business, why the company chose Japan as its business base, Japan's diverse fundraising opportunities and regulatory environment for regenerative medicine, and the company's growth strategy following its listing on the Tokyo Stock Exchange Growth Market. The article is available in English and can be accessed free of charge. We invite you to read it at the link below.

Article:
Why a European Biotech Chose Tokyo - Capital, Regulation, Talent: How Japan's Ecosystem Is Powering Innovacell's Regenerative Medicine Ambitions | Expert Perspectives - Insights - Investing in Japan - Japan External Trade Organization - JETRO

■ About Innovacell:

Innovacell Inc. was established in Japan in 2021 as the parent company of a regenerative medicine company spun off from the Medical University of Innsbruck in Austria, and was listed on the Tokyo Stock Exchange Growth Market in February 2026 (Securities Code: 504A).

Our Group aims to improve people's health and quality of life through the commercialization of cell therapy and regenerative medicine, and we are currently engaged in the research, development, and commercialization of regenerative medicine products for the treatment of incontinence (urge fecal incontinence, passive fecal incontinence, and stress urinary incontinence). To date, our Group has completed multiple clinical trials in Europe (including late-stage Phase II trials) for two pipeline programs: ICEF15 (target indication: urge fecal incontinence) and ICES13 (target indication: stress urinary incontinence). For more details, please visit our website or our YouTube channel.

End